Previous 10 | Next 10 |
The stock crash of 2020 has produced a lot of losers. But it’s also forged some winners. One of the industries that is most likely to benefit from the COVID-19 outbreak and profit in the long-term is biotech. Sure, they’re not always the most stable investments. Firms t...
Trillium Therapeutics (NASDAQ: TRIL ) has filed a prospectus for a $250M mixed shelf offering. More news on: Trillium Therapeutics Inc., Healthcare stocks news, , Read more ...
Are These On Your Penny Stocks Watch List In 2020? I’m pretty sure that most people don’t think about penny stocks and analyst ratings at first. From what I’m sure many of you initially experienced, penny stocks have been known for volatile trading of “start-up...
With everything that's going on with the COVID-19 pandemic, many healthcare companies have grabbed plenty of spotlight during these challenging times. At the same time, a number of otherwise promising businesses have slipped under the radar. That's especially true for small-cap biotech stocks...
Shares of Trillium Therapeutics ( TRIL ) have risen by 21% since my January article recommended scooping up shares of this "fast follower" in the potentially lucrative CD47 space. With shares trying to break above the 50-day moving average ahead of what I call a "needle-moving" catalyst, I...
First patients in the 1.4 mg/kg cohort of TTI-621 and the 8.0 mg/kg cohort of TTI-622 clinical studies have been dosed. Going forward, expect a slow-down or potentially a pause in enrollment of new patients. Sufficient drug supply inventory in place to complete ongoing studies. Curren...
The coronavirus outbreak and the effects of COVID-19 have gone deeper and wider than most people would have expected. That applies just as much to markets as anywhere. Whether it's a tech sector that is supporting our new work from home or re-rating as expensive EV/Sales multiples make less se...
If you threw a dart at a dartboard covered with every stock ticker on the market, the odds are overwhelmingly in favor of you hitting a stock that's down so far in 2020. Only a few have managed to rise in the midst of the massive meltdown caused by the novel coronavirus pandemic. Even fewer have...
A string of scientific breakthroughs in recent years has made oncology the most-watched corner of the biopharmaceutical industry, and many of those breakthroughs were first presented at the American Society of Clinical Oncology's (ASCO) annual meeting. However, gathering scientists from all ove...
The race is on for a vaccine for the coronavirus. Over the last 24 hours, up to 9,000 have been infected with the virus just in the U.S. Up to 149 have now died. Worse, according to the U.S. government, the pandemic could last 18 months or longer, and “include multiple waves of illness...
News, Short Squeeze, Breakout and More Instantly...
Trillium Therapeutics Inc. Company Name:
TRIL Stock Symbol:
NASDAQ Market:
Trillium Therapeutics Inc. Website:
The emerging psychedelics industry is expanding rapidly across the globe. With research demonstrating promising therapeutic potential for substance...
In this clip from "The Pharma & Biotech Show" on Motley Fool Live , recorded on Feb. 2 , Motley Fool contributors Keith Speights and Brian Orelli explain why the news of a discontinued drug from the pharmaceutical giant hasn't shaken investors. Keith Speights: Pf...
CAMBRIDGE, Mass., Oct. 28, 2021 (GLOBE NEWSWIRE) -- Trillium Therapeutics Inc. (“Trillium” or the “Company”) (NASDAQ/TSX: TRIL) , a clinical stage immuno-oncology company developing innovative therapies for the treatment of cancer, is pleased to announce...